ETC-1002, a Non-Statin, Lowers LDL Cholesterols and Appears to Guard Against Other Risks
Sunday, March 25, 2012 - 08:30
in Health & Medicine
Early data suggest ETC-1002, a drug that regulates lipid and carbohydrate metabolism, had a significant impact on cholesterol levels and improved factors believed to contribute to cardio-metabolic diseases, say researchers from the Methodist DeBakey Heart & Vascular Center, the Baylor College of Medicine, and Esperion Therapeutics, Inc.